PE-22-28 Dosage Guide

PE-22-28, also known as PACAP(22-28), is a synthetic heptapeptide (7 amino acids) derived from Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP). It corresponds to positions 22–28 of the full-length PACAP sequence and is designed to selectively activate the PAC1 receptor — the primary PACAP receptor in the central nervous system — while having reduced activity at the VPAC1 and VPAC2 receptors.

This selectivity is the core rationale for PE-22-28's existence. Full-length PACAP (a 38-amino-acid neuropeptide) is one of the most potent neuroprotective molecules known, but it activates all three PACAP receptors: PAC1, VPAC1, and VPAC2. While PAC1 activation in the brain drives the desirable neuroprotective and neurotrophic effects — including BDNF and NGF upregulation, cAMP/PKA-mediated anti-apoptotic signaling, and enhancement of synaptic plasticity — VPAC1 and VPAC2 activation in peripheral tissues causes significant vasodilation, flushing, hypotension, and gastrointestinal effects. PE-22-28 aims to deliver the brain benefits of PACAP without these systemic side effects.

PE-22-28 is a relatively new entrant to the research peptide community, emerging around 2020–2022. It is primarily administered intranasally to leverage nose-to-brain delivery pathways (olfactory and trigeminal nerve transport), though subcutaneous injection is also used. The evidence base for PE-22-28 specifically is limited — most supporting research comes from studies on full-length PACAP and its receptor pharmacology.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

New to peptides? Start with the Beginner's Guide to Peptides.

PE-22-28 is administered intranasally (primary community route) or by subcutaneous injection. Intranasal delivery is preferred because it provides more direct access to the CNS via olfactory and trigeminal nerve pathways, which is particularly relevant for a neuroprotective peptide targeting brain PAC1 receptors. Subcutaneous injection provides more reliable systemic absorption but requires the peptide to cross the blood-brain barrier.

Intranasal Dosage by Experience Level

Subcutaneous Dosage by Experience Level

Administration Timing

• Morning administration preferred: PE-22-28's neurotrophic effects align well with daytime cognitive demands; morning dosing is the most common community practice
• If dosing twice daily: Morning + early afternoon (e.g., 8 AM + 1 PM); avoid late evening dosing as some users report mild stimulatory effects that may interfere with sleep
• Intranasal technique matters: Clear nasal passages before administering, tilt head slightly forward, aim spray toward outer nasal wall (not septum), sniff gently — do not inhale forcefully
• No fasting requirement: Unlike GHRPs, PE-22-28 does not require fasted administration; food intake does not significantly affect PAC1 receptor activation

PE-22-28 is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. For subcutaneous injection, reconstitute with bacteriostatic water and draw your dose with an insulin syringe. For intranasal use, reconstitute and transfer to a nasal spray device (see section above).

Quick Reference — 5 mg Vial (SubQ)

There is no clinical data establishing optimal cycling protocols for PE-22-28. The cycling recommendations below are based on general peptide cycling principles, the theoretical concern of PAC1 receptor downregulation with chronic stimulation, and community experience. The honest answer is that nobody knows the ideal cycle length for PE-22-28. These protocols represent a reasonable, cautious approach.

Why Cycling Is Recommended

PAC1 receptors, like most G protein-coupled receptors (GPCRs), can undergo desensitization and internalization with chronic agonist exposure. While the specific desensitization kinetics of PAC1 in response to PE-22-28 are unknown, the general principle of GPCR desensitization supports periodic cycling. Additionally, BDNF and other neurotrophic factors have complex dose-response relationships — chronic supraphysiological stimulation may not produce better outcomes than pulsed exposure.

What to Use During Off-Cycles

During PE-22-28 off-cycles, users seeking continued nootropic or neuroprotective support often switch to peptides that work through different receptor systems:

• Semax — works through melanocortin and TrkB pathways; no PAC1 involvement; complementary BDNF upregulation through different signaling
• Selank — modulates enkephalin metabolism and GABA signaling; provides anxiolytic and neuroprotective effects independent of PACAP pathways
• BPC-157 — neuroprotection via nitric oxide pathway, growth factor modulation, and gut-brain axis support; no PAC1 involvement

Reported Side Effects

Mild and generally self-limiting (community reports):

• Nasal irritation, dryness, or mild congestion — most common with intranasal route; usually resolves with alternating nostrils and saline spray use
• Mild headache — reported by some users, particularly in the first few days; may relate to cAMP-mediated vasodilation (a downstream effect of PAC1 activation)
• Mild dizziness or lightheadedness — occasionally reported; typically transient
• Transient fatigue — some users report feeling slightly tired in the first week; usually resolves with continued use
• Injection site reaction — mild redness or soreness with subcutaneous administration

Theoretical Concerns from PACAP Research

Full-length PACAP is associated with effects that PE-22-28's PAC1 selectivity is designed to minimize. However, because the degree of PE-22-28's VPAC1/VPAC2 selectivity in vivo is not precisely characterized, these potential effects should be considered:

• Vasodilation and flushing — full-length PACAP causes significant vasodilation via VPAC receptors. PE-22-28's PAC1 selectivity should reduce this, but residual VPAC activity cannot be ruled out at higher doses
• Blood pressure changes — PACAP-mediated vasodilation can lower blood pressure. Monitor if you have pre-existing hypotension
• Migraine triggering — PACAP is a known migraine trigger in susceptible individuals. While this is thought to be primarily VPAC-mediated, PAC1 may also play a role. Users with migraine history should exercise caution
• Stress response modulation — PACAP is involved in the HPA axis stress response. Paradoxical anxiety or agitation is theoretically possible in some individuals

Contraindications

• Active cancer or history of cancer — PACAP/PAC1 signaling promotes cell survival and proliferation. Elevated cAMP, BDNF, and anti-apoptotic signaling could theoretically support tumor growth or prevent apoptosis of malignant cells. Avoid with active malignancies.
• Pregnancy and breastfeeding — no safety data exists for PE-22-28 during pregnancy or nursing. PACAP plays roles in embryonic development. Avoid entirely.
• Migraine history — PACAP is a well-established migraine trigger. While PE-22-28's PAC1 selectivity may reduce this risk compared to full-length PACAP, users with migraine should start at the lowest dose and discontinue if migraines worsen.
• Hypotension — if PE-22-28 retains any VPAC activity, it could contribute to vasodilation and blood pressure reduction. Use with caution in individuals with low baseline blood pressure.
• Pituitary or hypothalamic disorders — PACAP/PAC1 signaling is heavily involved in pituitary function and HPA axis regulation. Pre-existing disorders of these systems are a contraindication.

When to Stop or Reduce Dose

• Persistent or severe headache (especially if you have migraine history)
• Increased anxiety, agitation, or restlessness (PACAP's complex role in stress response means this is possible in some individuals)
• Flushing, warmth, or blood pressure changes (potential VPAC activation at higher doses)
• Persistent nasal irritation or nosebleeds with intranasal use — switch to SubQ or take a break
• Any symptom that feels unusual or concerning — with a poorly characterized peptide, err on the side of caution